These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1648507)

  • 41. Interleukin-5 is an autocrine growth factor for Epstein-Barr virus-transformed B lymphocytes.
    Baumann MA; Paul CC
    Blood; 1992 Apr; 79(7):1763-7. PubMed ID: 1313713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
    Konttinen YT; Bluestein HG; Zvaifler NJ
    J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Capacity of B-lymphocytic lines of diverse tumor origin to produce and respond to B-cell growth factors: a progression model for B-cell lymphomagenesis.
    Gordon J; Aman P; Rosén A; Ernberg I; Ehlin-Henriksson B; Klein G
    Int J Cancer; 1985 Feb; 35(2):251-6. PubMed ID: 2982745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement of EBV transformation and cloning efficiency of human B cells using culture supernatants from lymphoblastoid cell lines.
    Mevissen ML; Kwekkeboom J; Goormachtig E; Lindhout E; de Groot C
    Hum Antibodies Hybridomas; 1993 Apr; 4(2):66-73. PubMed ID: 8390865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus.
    Baran-Marszak F; Laguillier C; Youlyouz I; Feuillard J; Mariette X; Fagard R; Raphaël M
    Cytokine; 2006 Mar; 33(6):337-45. PubMed ID: 16713282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TIMP-1/MMP-9 imbalance in an EBV-immortalized B lymphocyte cellular model: evidence for TIMP-1 multifunctional properties.
    Gaudin P; Trocmé C; Berthier S; Kieffer S; Boutonnat J; Lamy C; Surla A; Garin J; Morel F
    Biochim Biophys Acta; 2000 Dec; 1499(1-2):19-33. PubMed ID: 11118636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tyrosines 60, 64, and 101 of Epstein-Barr virus LMP2A are not essential for blocking B cell signal transduction.
    Swart R; Fruehling S; Longnecker R
    Virology; 1999 Oct; 263(2):485-95. PubMed ID: 10544120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.
    Kryworuckho M; Diaz-Mitoma F; Kumar A
    Immunology; 1995 Sep; 86(1):41-8. PubMed ID: 7590880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Search for infectious Epstein-Barr virus-releasing cell lines, with particular reference to a new producer line, NHAd-60.
    Sakamoto K
    Gan; 1977 Apr; 68(2):145-50. PubMed ID: 196968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infection of leukaemic B lymphocytes by Epstein Barr virus.
    Doyle MG; Catovsky D; Crawford DH
    Leukemia; 1993 Nov; 7(11):1858-64. PubMed ID: 8231253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogeneity of EBV-transformable human B lymphocyte populations.
    Chan MA; Stein LD; Dosch HM; Sigal NH
    J Immunol; 1986 Jan; 136(1):106-12. PubMed ID: 2999241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
    Aguirre AJ; Robertson ES
    J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A mechanism of T cell regulation of Epstein-Barr virus latency.
    Frugoni P; Pike SE; Tosato G
    Cell Immunol; 1993 Apr; 147(2):256-66. PubMed ID: 8095857
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between immunoglobulin production and immortalization by Epstein Barr virus.
    Tosato G; Blaese RM; Yarchoan R
    J Immunol; 1985 Aug; 135(2):959-64. PubMed ID: 2989369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system.
    Condino-Neto A; Newburger PE
    Arch Biochem Biophys; 1998 Dec; 360(2):158-64. PubMed ID: 9851826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
    D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
    J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immortalized Epstein-Barr virus-positive B-cell lines obtained by prolonged culture of peripheral blood mononuclear cells from human immunodeficiency virus type 1-positive patients.
    Ruibal-Ares B; Belmonte L; Baré P; Scolnik M; Palacios MF; Bayo-Hanza C; Galmarini CM; Mendez G; de Bracco MM
    J Hum Virol; 2001; 4(4):200-13. PubMed ID: 11694848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ.
    Jud A; Kotur M; Berger C; Gysin C; Nadal D; Lünemann A
    Oncotarget; 2017 Jan; 8(4):6130-6141. PubMed ID: 28008151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.